Migraine following the use of a 5-hydroxytryptamine antagonist.
Siderov
J
J
Zalcberg
J
J
Chambers
B
B
Fabinyi
G
G
D004878:Ergotamine / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008875:Middle Aged; D008881:Migraine Disorders / Q000139:chemically induced* / Q000188:drug therapy; D009837:Oligodendroglioma / Q000188:drug therapy; D017294:Ondansetron / Q000009:adverse effects*; D018170:Sumatriptan / Q000627:therapeutic use
D017294:Ondansetron; D018170:Sumatriptan; D004878:Ergotamine